Read about Primmune Therapeutics' Series B extension and their plans to revolutionize solid tumor immunotherapy with a novel TLR7 agonist. Learn more.
San Diego-based clinical-stage biotech company Primmune Therapeutics has announced an additional close of its Series B financing round for $8.6 million, bringing the total round to $23.3 million. Investors in the round included Bioqube Ventures, Oberland Capital and Samsara Biocapital.
Primmune Therapeutics will use the funding to advance clinical testing of an oral drug designed to activate the immune system to fight solid tumors. The company plans to launch a Phase 2 study testing PRTX007 together with standard anti-PD-1 therapy in patients with Stage III melanoma that can be removed by surgery. The study will examine how well the treatment works when given before surgery. It will be conducted entirely in Australia by Primmune Therapeutics Pty Ltd. with Novotech, a contract research organization and scientific advisory firm. “This financing enables us to rapidly advance PRTX007 into a clearly defined proof-of-principle study with validated efficacy and safety endpoints, with the goal of establishing PRTX007 as a class-leading immunotherapy option for patients with solid tumors,” said Charlie McDermott, chief executive and director of Primmune Therapeutics, in a statement. Founded in 2017 by James Appleman, Paulo Rangel and Stephen Webber, Primmune Therapeutics designs and develops orally administered, novel small molecule, toll-like receptor 7 agonists as immunotherapies for the treatment of cancer and other diseases responsive to immunotherapy. The tumor drug that it is testing activates the immune system in a more targeted way. It is designed to boost beneficial immune responses that help fight disease, while avoiding excessive inflammation that has limited similar treatments in the past. It has been tested in more than 100 healthy volunteers across two Phase 1 clinical studies. Results showed that it produced the intended immune response without triggering unwanted inflammation and was generally well tolerated, with no serious side effects reported. Information for this article was sourced from Primmune Therapeutics.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Exercise mimetics may act as a "biological spark plug" for the depressed brain.A new study explores exercise mimetics as novel therapeutics for depression by triggering muscle-to-brain signals that support mood regulation and resilience.
Read more »
Undrafted Rookie Lawson Lovering Notches Double-Double in Memphis WinThe Grizzlies have multiple solid young players on the roster, and may have found another contributor over the past few games.
Read more »
Instant Takeaways From Georgia Tech's 87-70 Loss vs No. 21 LouisvilleGeorgia Tech never led on the road against No 21 Louisville and despite playing solid basketball in the second half, the Yellow Jackets lost to the Cardinals 87
Read more »
7 Epic Fantasy Shows That Were Great From Beginning to EndThese seven fantasy series are solid watches from start to finish -- and you don't want to miss them.
Read more »
Donut Lab promises proof for breakthrough solid-state battery after ‘scam’ claimsDonut Lab says independent test results will go public on February 23 to counter growing solid-state battery skepticism.
Read more »
Yep, it’s fast: Donut Lab’s solid-state battery gets its first test resultDonut Lab’s solid-state battery can charge from 0 to 80 percent in under 5 minutes without an extensive cooling system.
Read more »